Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Article

Abstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown

Palabras claves:

immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, Vaccine

Autores:

Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.

Fuentes:

scopus